Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 670 matching trials from the live ClinicalTrials.gov search.
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration, X-linked Retinoschisis, Retinal Dystrophies
Interventions
Not listed
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Conditions
Age-Related Macular Degenerations., Subfoveal Neovascularization.
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
51 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions
Vitamin A Palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Conditions
Age Related Macular Degeneration
Interventions
ForeseeHome
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OPT-302, ranibizumab, sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
Conditions
Dry Macular Degeneration, Geographic Atrophy
Interventions
CPCB-RPE1
Biological
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 3 more
Conditions
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
Device
Lead sponsor
i-Lumen Scientific, Inc.
Industry
Eligibility
50 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
Conditions
Intermediate Age-Related Macular Degeneration
Interventions
Whole Egg - 4, Whole Egg - 2
Drug
Lead sponsor
Kathryn Starr
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Age Factor, Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Age-Related Macular Degeneration, Macular Degeneration
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60

NCT00121589
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Wet Age-related Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
65
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Povidone Iodine, Hypochlorous Acid
Other
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Lucentis (Ranibizumab)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Nidek MP-3
Device
Lead sponsor
Doheny Image Reading Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pasadena, California
Conditions
Neovascular Age Related Macular Degeneration
Interventions
RTH258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
Conditions
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
61
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York